THIS PROJECT WILL PRODUCE MOUSE AND RAT MONOCLONAL ANTIBODIES TO THE LEUKEMOGENIC HUMAN RETROVIRUS, HTLV-I.

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
N/A
Agency Tracking Number:
4796
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Gene Labs Inc
871 Industrial Road, Building J, San Carlos, CA, 94070
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 KOU HWANG
 PRINCIPAL INVESTIGATOR
 (415) 594-1600
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THIS PROJECT WILL PRODUCE MOUSE AND RAT MONOCLONAL ANTIBODIES TO THE LEUKEMOGENIC HUMAN RETROVIRUS, HTLV-I. STABLE, IMMUNOGLOBULIN-SECRETING HTLV-I ELISA-REACTIVE SUBCLONES WILL BE ISOLATED AND THEIR VIRAL ANTIGEN SPECIFICITY CONFIRMED BY IMMUNOPRECIPITATION, WESTERN BLOTTING, AND IMMUNOFLUORESCENCE ANALYSIS. THE BINDING CONSTANTS OF THE ANTIBODIES PRODUCED WILL BE DETERMINED. ITIS ANTICIPATED THAT IN A PHASE II PROJECT, FINE SPECIFICITY MAPPING OF THE ANTIBODIES WILL BE PERFORMED AND THEIR BIOLOGICAL EFFECTS CHARACTERIZED. PRELIMINARY STUDIES, RESULTING IN THE SUCCESSFUL GENERATION OF A MURINE MONOCLONAL ANTIBODY TO AN HTLV-I ANTIGEN, HAVE ALREADY DEMONSTRATED THE FEASIBILITY OF THE PROPOSED APPROACH. SUCCESSFUL GENERATION OF HIGH AVIDITY MOUSE AND RAT MONOCLONALS SHOULD PROVIDE REAGENTS WITH IMPROVED DIAGNOSTICPOTENTIAL AND POSSIBLE THERAPEUTIC UTILITY.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government